Last checked at 4 May 2017 13:30
For immediate release | 4 May 2017 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:
(a) Identity of the significant shareholder: Mr Nigel Wray
(b) Date of disclosure: 3 May 2017
(c) Date of relevant change: 3 May 2017
(d) Price, amount and class: 8,093,312 ordinary shares of 1p each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 1.63% (direct) and 3.68% (indirect) = 5.31% total
In compliance with DTR5, a copy of the notification received from this investor is appended.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer |
|
Rob Bellhouse, Company Secretary |
|
www.alliancepharma.co.uk |
|
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover |
|
|
|
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield |
|
Corporate Broking: James Black / Toby Adcock |
|
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
|
| |||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | ALLIANCE PHARMA PLC | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | √ | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
| |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
| |||
An event changing the breakdown of voting rights |
| |||
Other (please specify): | Placing shares and exercise of broker's option |
| ||
3. Full name of person(s) subject to thenotification obligation: | NIGEL WRAY | |||
4. Full name of shareholder(s) (if different from 3.): | Jarvis Investment Management Nominees Limited UBS PRIVATE BANKING NOMINEES LTD ROY NOMINEES LIMITED | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 3 May 2017 | |||
6. Date on which issuer notified: | 3 May 2017 | |||
7. Threshold(s) that is/are crossed orreached: | 5% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
Ordinary shares GB0031030819 | 33,185,905 | 33,185,905 | 7,708,005 | 7,708,005 | 17,384,588 | 1.63% | 3.68% | |||||||||
| ||||||||||||||||
| ||||||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
|
|
|
|
| ||||||||||||
| ||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
|
|
|
|
| Nominal | Delta | ||||||||||
|
| |||||||||||||||
| ||||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
25,092,593
| 5.3% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees 7,551,269 held by UBS Private Banking Nominees Ltd
156,736- Jarvis Investment Management Nominees Limited The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited - 17,384,588 | ||
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | N/A | |
11. Number of voting rights proxy holder will ceaseto hold: | N/A | |
12. Date on which proxy holder will cease to holdvoting rights: | N/A | |
| ||
13. Additional information: | Figures are based on a total number of voting rights of 472,795,052
| |
14. Contact name: | Nigel Wray | |
15. Contact telephone number: | 020 7647 7647 | |